From the Journals
Clinical Guidelines
Optimizing the Care of Patients With Higher-Risk Myelofibrosis
-
By
-
March 26, 2025
-
6 min
-
1
Myelofibrosis is characterized by JAK-STAT pathway disruption.
-
2
Diagnosis requires three major criteria plus one minor criterion.
-
3
Risk stratification is vital for treatment decisions.
-
4
Allogeneic stem cell transplantation is the only curative option.
-
5
Several JAK inhibitors are FDA-approved for symptom management.
-
6
Adverse effects of treatment include cytopenias and infections.
-
7
Regular monitoring of symptoms and side effects is essential.
-
8
New therapies like luspatercept are emerging for anemia management.
